Heart failure & cardiomyopathiesCohort study
Long-Term Efficacy and Safety of Tailored Immunosuppressive Therapy in Immune-Mediated Biopsy-Proven Myocarditis: A Propensity-Weighted Study
- Retrospective cohort study
- propensity-score weighted
IS managed by a multidisciplinary Cardioimmunology Team with a safety checklist and active patients' education
Authors' conclusion
Prolonged tailored IS is effective and safe in BP immune-mediated myocarditis irrespective of histology and clinical presentation.
Study context
- Population
- Consecutive patients with biopsy-proven immune-mediated myocarditis, irrespective of histology and clinical presentation
- Participants
- 91 vs 267
- Exposure
- Long-term tailored IS on top of optimal medical therapy (OMT) vs OMT alone
- ISn = 91
- non-ISn = 267reference
- Outcome
- Composite of:
- Death
- Heart transplant
- Follow-up
- 5-year follow up
Main finding
As reported in the abstract
Death or heart transplant
Survival rate
Observational data: associations, not effects.
Secondary outcomes
Relapse · 5-year follow up
- Higher relapse rate with IS
Biventricular function and New York Heart Association (NYHA) class · follow-up
- Similar biventricular function and NYHA class with IS vs non-IS at follow-up, despite lower baseline biventricular function and higher risk profile with IS
Safety
Minor adverse drug reactions
- Minor adverse drug reactions, all resolved with therapy switch
- 13%
Original publication
Long-Term Efficacy and Safety of Tailored Immunosuppressive Therapy in Immune-Mediated Biopsy-Proven Myocarditis: A Propensity-Weighted Study. Eur J Heart Fail. Published 17 April 2024. doi:10.1002/ejhf.3220
Summarised from the published abstract; every number is checked against it